Pharmacogenetics of HMG-CoA reductase inhibitors: Optimizing the prevention of coronary heart disease

Current Pharmacogenomics and Personalized Medicine

Volumn 7 1, Issue , 2009, Pages 1-26

  Hu, M ^a   Mak, V W L ^a   Chu, T T W ^a   Waye, M M Y ^a   Tomlinson, B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Coronary heart disease; Ethnic differences; HMG CoA reductase inhibitors; LDL cholesterol; Pharmacogenetics

Indexed keywords

ATORVASTATIN; BAICALIN; BREAST CANCER RESISTANCE PROTEIN; CERIVASTATIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DILTIAZEM; FLUINDOSTATIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 2B7; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTIFUNGAL AGENT; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CARRIER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CHINESE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG UPTAKE; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; JAPANESE; LIPOPHILICITY; MEDICAL RESEARCH; MUSCLE DISEASE; MYOPATHY; NEGRO; PATIENT COMPLIANCE; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOPHORE; PREDICTION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; DOSE RESPONSE; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG RESPONSE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GRAPEFRUIT JUICE; HERB DRUG INTERACTION; HYPERLIPIDEMIA; IC 50; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; URINARY EXCRETION;

EID: 70249096009     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569209787582349     Document Type: Review

References (231)

1. Abifadel, M.; Varret, M.; Rabes, J. P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derre, A.; Villeger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J. M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N. G. and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156.
2. Albert, C. M.; Ma, J.; Rifai, N.; Stampfer, M. J. and Ridker, P. M. (2002) Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105, 2595-2599.
3. Ameyaw, M. M.; Regateiro, F.; Li, T.; Liu, X.; Tariq, M.; Mobarek, A.; Thornton, N.; Folayan, G. O.; Githang'a, J.; Indalo, A.; Ofori-Adjei, D.; Price-Evans, D. A. and McLeod, H. L. (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11, 217-221.
4. Arazi, S. S.; Genvigir, F. D.; Willrich, M. A.; Hirata, M. H.; Dorea, E. L.; Bernik, M. and Hirata, R. D. (2008) Atorvastatin effects on SREBP1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. Clin. Chim. Acta. 393(2), 119-124.
5. Backman, J. T.; Kyrklund, C.; Kivisto, K. T.; Wang, J. S. and Neuvonen, P. J. (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68, 122-129.
6. Backman, J. T.; Kyrklund, C.; Neuvonen, M. and Neuvonen, P. J. (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685-691.
7. Baigent, C.; Keech, A.; Kearney, P. M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R. and Simes, R. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278.
8. Ballantyne, C. M.; Herd, J. A.; Stein, E. A.; Ferlic, L. L.; Dunn, J. K.; Gotto, A. M., Jr. and Marian, A. J. (2000) Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J. Am. Coll. Cardiol. 36, 1572-1578.
9. Balram, C.; Zhou, Q.; Cheung, Y. B. and Lee, E. J. (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur. J. Clin. Pharmacol. 59, 123-126.
10. Bercovich, D.; Friedlander, Y.; Korem, S.; Houminer, A.; Hoffman, A.; Kleinberg, L.; Shochat, C.; Leitersdorf, E. and Meiner, V. (2006) The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 185, 97-107.
11. Berge, K. E.; Ose, L. and Leren, T. P. (2006) Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26, 1094-1100.
12. Beutler, E.; Gelbart, T. and Demina, A. (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 95, 8170-8174.
13. Blankenberg, S.; Rupprecht, H. J.; Bickel, C.; Jiang, X. C.; Poirier, O.; Lackner, K. J.; Meyer, J.; Cambien, F. and Tiret, L. (2003) Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J. Am. Coll. Cardiol. 41, 1983-1989.
14. Boekholdt, S. M.; Kuivenhoven, J. A.; Hovingh, G. K.; Jukema, J. W.; Kastelein, J. J. and van Tol, A. (2004) CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr. Opin. Lipidol. 15, 393-398.
15. Boekholdt, S. M.; Sacks, F. M.; Jukema, J. W.; Shepherd, J.; Freeman, D. J.; McMahon, A. D.; Cambien, F.; Nicaud, V.; de Grooth, G. J.; Talmud, P. J.; Humphries, S. E.; Miller, G. J.; Eiriksdottir, G.; Gudnason, V.; Kauma, H.; Kakko, S.; Savolainen, M. J.; Arca, M.; Montali, A.; Liu, S.; Lanz, H. J.; Zwinderman, A. H.; Kuivenhoven, J. A. and Kastelein, J. J. (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111, 278-287.
16. Bogman, K.; Peyer, A. K.; Torok, M.; Kusters, E. and Drewe, J. (2001) HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132, 1183-1192.
17. Brewer, H. B., Jr. (2003) Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 92, 23K-29K.
18. Carmena, R.; Roederer, G.; Mailloux, H.; Lussier-Cacan, S. and Davignon, J. (1993) The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 42, 895-901.
19. Cascorbi, I. (2003) Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur. J. Clin. Invest. 33(Suppl 2), 17-22.
20. Cascorbi, I. (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473.
21. Cha, S. H.; Sekine, T.; Fukushima, J. I.; Kanai, Y.; Kobayashi, Y.; Goya, T. and Endou, H. (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59, 1277-1286.
22. Chasman, D. I.; Posada, D.; Subrahmanyan, L.; Cook, N. R.; Stanton, V. P., Jr. and Ridker, P. M. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. World J. Gastroenterol. 291, 2821-2827.
23. Chaves, F. J.; Real, J. T.; Garcia-Garcia, A. B.; Civera, M.; Armengod, M. E.; Ascaso, J. F. and Carmena, R. (2001) Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J. Clin. Endocrinol. Metab. 86, 4926-4932.
24. Chen, S.; Tsybouleva, N.; Ballantyne, C. M.; Gotto, A. M., Jr. and Marian, A. J. (2004) Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14, 61-71.
25. Choi, J. H.; Lee, M. G.; Cho, J. Y.; Lee, J. E.; Kim, K. H. and Park, K. (2008) Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83, 251-257.
26. Choudhuri, S. and Klaassen, C. D. (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25, 231-259.
27. Christidis, D. S.; Liberopoulos, E. N.; Kakafika, A. I.; Miltiadous, G. A.; Liamis, G. L.; Kakaidi, B.; Tselepis, A. D.; Cariolou, M. A. and Elisaf, M. S. (2007) Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. Arch. Med. Res. 38, 403-410.
28. Chung, E.; Nafziger, A. N.; Kazierad, D. J. and Bertino, J. S., Jr. (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 79, 350-361.
29. Chung, J. Y.; Cho, J. Y.; Yu, K. S.; Kim, J. R.; Oh, D. S.; Jung, H. R.; Lim, K. S.; Moon, K. H.; Shin, S. G. and Jang, I. J. (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78, 342-350.
30. Corella, D.; Saiz, C.; Guillen, M.; Portoles, O.; Mulet, F.; Gonzalez, J. I. and Ordovas, J. M. (2000) Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis 152, 367-376.
31. Couture, P.; Brun, L. D.; Szots, F.; Lelievre, M.; Gaudet, D.; Despres, J. P.; Simard, J.; Lupien, P. J. and Gagne, C. (1998) Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18, 1007-1012.
32. Couvert, P.; Giral, P.; Dejager, S.; Gu, J.; Huby, T.; Chapman, M. J.; Bruckert, E. and Carrie, A. (2008) Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9, 1217-1227.
33. Crawford, D. C.; Sanders, C. L.; Qin, X.; Smith, J. D.; Shephard, C.; Wong, M.; Witrak, L.; Rieder, M. J. and Nickerson, D. A. (2006) Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 114, 2458-2465.
34. Dally, H.; Edler, L.; Jager, B.; Schmezer, P.; Spiegelhalder, B.; Dienemann, H.; Drings, P.; Schulz, V.; Kayser, K.; Bartsch, H. and Risch, A. (2003) The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13, 607-618.
35. Daly, A. K.; King, B. P. and Leathart, J. B. (2006) Genotyping for cytochrome P450 polymorphisms. Methods Mol. Biol. 320, 193-207.
36. Danik, J. S. and Ridker, P. M. (2007) Genetic determinants of C-reactive protein. Curr. Atheroscler. Rep. 9, 195-203.
37. de Grooth, G. J.; Zerba, K. E.; Huang, S. P.; Tsuchihashi, Z.; Kirchgessner, T.; Belder, R.; Vishnupad, P.; Hu, B.; Klerkx, A. H.; Zwinderman, A. H.; Jukema, J. W.; Sacks, F. M.; Kastelein, J. J. and Kuivenhoven, J. A. (2004) The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J. Am. Coll. Cardiol. 43, 854-857.
38. de Jong, F. A.; Marsh, S.; Mathijssen, R. H.; King, C.; Verweij, J.; Sparreboom, A. and McLeod, H. L. (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10, 5889-5894.
39. de Wildt, S. N.; Kearns, G. L.; Leeder, J. S. and van den Anker, J. N. (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37, 485-505.
40. Dedoussis, G. V.; Schmidt, H. and Genschel, J. (2004) LDL-receptor mutations in Europe. Hum. Mutat. 24, 443-459.
41. Deng, J. W.; Song, I. S.; Shin, H. J.; Yeo, C. W.; Cho, D. Y.; Shon, J. H. and Shin, J. G. (2008) The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet. Genomics 18, 424-433.
42. Donnelly, L. A.; Doney, A. S. F.; Dannfald, J.; Whitley, A. L.; Langa, C. C.; Morris, A. D.; Donnan, P. T. and Palmer, C. N. A. (2008) A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet. Genomics 18(12), 1021-1026.
43. Dreisbach, A. W.; Japa, S.; Sigel, A.; Parenti, M. B.; Hess, A. E.; Srinouanprachanh, S. L.; Rettie, A. E.; Kim, H.; Farin, F. M.; Hamm, L. L. and Lertora, J. J. (2005) The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am. J. Hypertens. 18, 1276-1281.
44. Dresser, G. K.; Spence, J. D. and Bailey, D. G. (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38, 41-57.
45. Fan, L.; Zhang, W.; Guo, D.; Tan, Z. R.; Xu, P.; Li, Q.; Liu, Y. Z.; Zhang, L.; He, T. Y.; Hu, D. L.; Wang, D. and Zhou, H. H. (2008) The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin. Pharmacol. Ther. 83, 471-476.
46. Fiegenbaum, M.; da Silveira, F. R.; Van der Sand, C. R.; Van der Sand, L. C.; Ferreira, M. E.; Pires, R. C. and Hutz, M. H. (2005a) Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin. Chim. Acta. 362, 182-188.
47. Fiegenbaum, M.; da Silveira, F. R.; Van der Sand, C. R.; Van der Sand, L. C.; Ferreira, M. E.; Pires, R. C. and Hutz, M. H. (2005b) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78, 551-558.
48. Fiegenbaum, M.; Silveira, F. R.; Van der Sand, C. R.; Van der Sand, L. C.; Ferreira, M. E.; Pires, R. C. and Hutz, M. H. (2005c) Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J. 5, 359-364.
49. Fromm, M. F. (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54, 1295-1310.
50. Fujino, H.; Yamada, I.; Shimada, S.; Yoneda, M. and Kojima, J. (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33, 27-41.
51. Furberg, C. D. and Pitt, B. (2001) Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. 2, 205-207.
52. Gao, Y.; Zhang, L. R. and Fu, Q. (2008) CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur. J. Clin. Pharmacol. 64(9), 877-882.
53. Garcia-Barcelo, M.; Chow, L. Y.; Chiu, H. F.; Wing, Y. K.; Lee, D. T.; Lam, K. L. and Waye, M. M. (2000) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem. 46, 18-23.
54. Garcia-Otin, A. L.; Civeira, F.; Aristegui, R.; Diaz, C.; Recalde, D.; Sol, J. M.; Masramon, X.; Hernandez, G. and Pocovi, M. (2002) Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. Eur. J. Clin. Invest. 32, 421-428.
55. Garg, A. and Simha, V. (2007) Update on dyslipidemia. J. Clin. Endocrinol. Metab. 92, 1581-1589.
56. Goodarzi, M. O.; Taylor, K. D.; Scheuner, M. T.; Antoine, H. J.; Guo, X.; Shah, P. K. and Rotter, J. I. (2007) Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts. Pharmacogenomics J. 7, 66-73.
57. Gruer, P. J.; Vega, J. M.; Mercuri, M. F.; Dobrinska, M. R. and Tobert, J. A. (1999) Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. 84, 811-815.
58. Guzman, E. C.; Hirata, M. H.; Quintao, E. C. and Hirata, R. D. (2000) Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin. Chem. Lab. Med. 38, 731-736.
59. Hasegawa, M.; Kusuhara, H.; Sugiyama, D.; Ito, K.; Ueda, S.; Endou, H. and Sugiyama, Y. (2002) Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J. Pharmacol. Exp. Ther. 300, 746-753.
60. Heath, K. E.; Gudnason, V.; Humphries, S. E. and Seed, M. (1999) The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 143, 41-54.
61. Himbergen, T. M.; van Tits, L. J.; Voorbij, H. A.; de Graaf, J.; Stalenhoef, A. F. and Roest, M. (2005) The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase- 1 in patients with familial hypercholesterolaemia. J. Intern. Med. 258, 442-449.
62. Hirano, M.; Maeda, K.; Hayashi, H.; Kusuhara, H. and Sugiyama, Y. (2005a) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314, 876-882.
63. Hirano, M.; Maeda, K.; Matsushima, S.; Nozaki, Y.; Kusuhara, H. and Sugiyama, Y. (2005b) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68, 800-807.
64. Ho, R. H.; Leake, B. F.; Roberts, R. L.; Lee, W. and Kim, R. B. (2004) Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J. Biol. Chem. 279, 7213-7222.
65. Ho, R. H.; Tirona, R. G.; Leake, B. F.; Glaeser, H.; Lee, W.; Lemke, C. J.; Wang, Y. and Kim, R. B. (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806.
66. Ho, R. H.; Choi, L.; Lee, W.; Mayo, G.; Schwarz, U. I.; Tirona, R. G.; Bailey, D. G.; Michael Stein, C. and Kim, R. B. (2007) Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics 17, 647-656.
67. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M. and Brinkmann, U. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478.
68. Hsiang, B.; Zhu, Y.; Wang, Z.; Wu, Y.; Sasseville, V.; Yang, W. P. and Kirchgessner, T. G. (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168.
69. Hsieh, K. P.; Lin, Y. Y.; Cheng, C. L.; Lai, M. L.; Lin, M. S.; Siest, J. P. and Huang, J. D. (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29, 268-273.
70. Huang, L.; Wang, Y. and Grimm, S. (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab. Dispos. 34, 738-742.
71. Humphries, S. E.; Yiannakouris, N. and Talmud, P. J. (2008) Cardiovascular disease risk prediction using genetic information (gene scores): is it really informative? Curr. Opin. Lipidol. 19, 128-132.
72. Hustert, E.; Haberl, M.; Burk, O.; Wolbold, R.; He, Y. Q.; Klein, K.; Nuessler, A. C.; Neuhaus, P.; Klattig, J.; Eiselt, R.; Koch, I.; Zibat, A.; Brockmoller, J.; Halpert, J. R.; Zanger, U. M. and Wojnowski, L. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773-779.
73. Iakoubova, O. A.; Sabatine, M. S.; Rowland, C. M.; Tong, C. H.; Catanese, J. J.; Ranade, K.; Simonsen, K. L.; Kirchgessner, T. G.; Cannon, C. P.; Devlin, J. J. and Braunwald, E. (2008a) Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 51, 449-455.
74. Iakoubova, O. A.; Tong, C. H.; Rowland, C. M.; Kirchgessner, T. G.; Young, B. A.; Arellano, A. R.; Shiffman, D.; Sabatine, M. S.; Campos, H.; Packard, C. J.; Pfeffer, M. A.; White, T. J.; Braunwald, E.; Shepherd, J.; Devlin, J. J. and Sacks, F. M. (2008b) Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 51, 435-443.
75. Ieiri, I.; Suwannakul, S.; Maeda, K.; Uchimaru, H.; Hashimoto, K.; Kimura, M.; Fujino, H.; Hirano, M.; Kusuhara, H.; Irie, S.; Higuchi, S. and Sugiyama, Y. (2007) SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 82, 541-547.
76. Igel, M.; Sudhop, T. and von Bergmann, K. (2002) Pharmacology of 3- hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J. Clin. Pharmacol. 42, 835-845.
77. Iida, A.; Saito, S.; Sekine, A.; Mishima, C.; Kondo, K.; Kitamura, Y.; Harigae, S.; Osawa, S. and Nakamura, Y. (2001) Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J. Hum. Genet. 46, 668-683.
78. Ishikawa, C.; Ozaki, H.; Nakajima, T.; Ishii, T.; Kanai, S.; Anjo, S.; Shirai, K. and Inoue, I. (2004) A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J. Hum. Genet. 49, 582-585.
79. Ito, K.; Oleschuk, C. J.; Westlake, C.; Vasa, M. Z.; Deeley, R. G. and Cole, S. P. (2001) Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem. 276, 38108-38114.
80. Ito, S.; Ieiri, I.; Tanabe, M.; Suzuki, A.; Higuchi, S. and Otsubo, K. (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/ cMOAT, in healthy Japanese subjects. Pharmacogenetics 11, 175-184.
81. Itoda, M.; Saito, Y.; Soyama, A.; Saeki, M.; Murayama, N.; Ishida, S.; Sai, K.; Nagano, M.; Suzuki, H.; Sugiyama, Y.; Ozawa, S. and Sawada Ji, J. (2002) Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab. Dispos. 30, 363-364.
82. Jada, S. R.; Xiaochen, S.; Yan, L. Y.; Xiaoqiang, X.; Lal, S.; Zhou, S. F.; Ooi, L. L. and Chowbay, B. (2007) Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur. J. Clin. Pharmacol. 63, 555-563.
83. Jang, Y.; Kim, O. Y.; Hyun, Y. J.; Chae, J. S.; Koh, S. J.; Heo, Y. M.; Choi, D.; Shin, D. J.; Huttner, K. and Lee, J. H. (2008) Interleukin-6- 572C>G polymorphism-association with inflammatory variables in Korean men with coronary artery disease. Transl. Res. 151, 154-161.
84. Jeenah, M.; September, W.; Graadt van Roggen, F.; de Villiers, W.; Seftel, H. and Marais, D. (1993) Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 98, 51-58.
85. Jones, P.; Kafonek, S.; Laurora, I. and Hunninghake, D. (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81, 582-587.
86. Jones, P. H.; Davidson, M. H.; Stein, E. A.; Bays, H. E.; McKenney, J. M.; Miller, E.; Cain, V. A. and Blasetto, J. W. (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152-160.
87. Kajinami, K.; Yagi, K.; Higashikata, T.; Inazu, A.; Koizumi, J. and Mabuchi, H. (1998) Low-density lipoprotein receptor genotypedependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am. J. Cardiol. 82, 113-117.
88. Kajinami, K.; Brousseau, M. E.; Nartsupha, C.; Ordovas, J. M. and Schaefer, E. J. (2004a) ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 45, 653-656.
89. Kajinami, K.; Brousseau, M. E.; Ordovas, J. M. and Schaefer, E. J. (2004b) CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93, 104-107.
90. Kajinami, K.; Brousseau, M. E.; Ordovas, J. M. and Schaefer, E. J. (2004c) Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 175, 287-293.
91. Kajinami, K.; Brousseau, M. E.; Ordovas, J. M. and Schaefer, E. J. (2004d) Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol. 93, 1046-1050.
92. Kajinami, K.; Takekoshi, N.; Brousseau, M. E. and Schaefer, E. J. (2004e) Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177, 219-234.
93. Kajinami, K.; Brousseau, M. E.; Lamon-Fava, S.; Ordovas, J. M. and Schaefer, E. J. (2005a) Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis 178, 331-338.
94. Kajinami, K.; Brousseau, M. E.; Ordovas, J. M. and Schaefer, E. J. (2005b) A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 180, 407-415.
95. Kajinami, K.; Okabayashi, M.; Sato, R.; Polisecki, E. and Schaefer, E. J. (2005c) Statin pharmacogenomics: what have we learned, and what remains unanswered? Curr. Opin. Lipidol. 16, 606-613.
96. Karayan, L.; Qiu, S.; Betard, C.; Dufour, R.; Roederer, G.; Minnich, A.; Davignon, J. and Genest, J., Jr. (1994) Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene. Arterioscler. Thromb. 14, 1258-1263.
97. Kathiresan, S.; Melander, O.; Guiducci, C.; Surti, A.; Burtt, N. P.; Rieder, M. J.; Cooper, G. M.; Roos, C.; Voight, B. F.; Havulinna, A. S.; Wahlstrand, B.; Hedner, T.; Corella, D.; Tai, E. S.; Ordovas, J. M.; Berglund, G.; Vartiainen, E.; Jousilahti, P.; Hedblad, B.; Taskinen, M. R.; Newton-Cheh, C.; Salomaa, V.; Peltonen, L.; Groop, L.; Altshuler, D. M. and Orho-Melander, M. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189-197.
98. Kim, K. A.; Chung, J.; Jung, D. H. and Park, J. Y. (2004) Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur. J. Clin. Pharmacol. 60, 575-581.
99. Kim, K. A.; Park, P. W.; Lee, O. J.; Kang, D. K. and Park, J. Y. (2007) Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 47, 87-93.
100. Kim, R. B.; Leake, B. F.; Choo, E. F.; Dresser, G. K.; Kubba, S. V.; Schwarz, U. I.; Taylor, A.; Xie, H. G.; McKinsey, J.; Zhou, S.; Lan, L. B.; Schuetz, J. D.; Schuetz, E. G. and Wilkinson, G. R. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199.
101. Kimchi-Sarfaty, C.; Gribar, J. J. and Gottesman, M. M. (2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62, 1-6.
102. King, L. M.; Gainer, J. V.; David, G. L.; Dai, D.; Goldstein, J. A.; Brown, N. J. and Zeldin, D. C. (2005) Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet. Genomics 15, 7-13.
103. Kirchheiner, J.; Kudlicz, D.; Meisel, C.; Bauer, S.; Meineke, I.; Roots, I. and Brockmoller, J. (2003) Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)- 3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 74, 186-194.
104. Kivisto, K. T.; Niemi, M.; Schaeffeler, E.; Pitkala, K.; Tilvis, R.; Fromm, M. F.; Schwab, M.; Eichelbaum, M. and Strandberg, T. (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14, 523-525.
105. Kivisto, K. T. and Niemi, M. (2007) Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24, 239-247.
106. Konig, J.; Seithel, A.; Gradhand, U. and Fromm, M. F. (2006) Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372, 432-443.
107. Kooner, J. S.; Chambers, J. C.; Aguilar-Salinas, C. A.; Hinds, D. A.; Hyde, C. L.; Warnes, G. R.; Gomez Perez, F. J.; Frazer, K. A.; Elliott, P.; Scott, J.; Milos, P. M.; Cox, D. R. and Thompson, J. F. (2008) Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat. Genet. 40, 149-151.
108. Krishnamurthy, P. and Schuetz, J. D. (2006) Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46, 381-410.
109. Kroetz, D. L.; Pauli-Magnus, C.; Hodges, L. M.; Huang, C. C.; Kawamoto, M.; Johns, S. J.; Stryke, D.; Ferrin, T. E.; DeYoung, J.; Taylor, T.; Carlson, E. J.; Herskowitz, I.; Giacomini, K. M. and Clark, A. G. (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13, 481-494.
110. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S. and Schuetz, E. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391.
111. Kuivenhoven, J. A.; Jukema, J. W.; Zwinderman, A. H.; de Knijff, P.; McPherson, R.; Bruschke, A. V.; Lie, K. I. and Kastelein, J. J. (1998) The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338, 86-93.
112. Kyrklund, C.; Backman, J. T.; Kivisto, K. T.; Neuvonen, M.; Laitila, J. and Neuvonen, P. J. (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69, 340-345.
113. Lahera, V.; Goicoechea, M.; de Vinuesa, S. G.; Miana, M.; de las Heras, N.; Cachofeiro, V. and Luno, J. (2007) Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr. Med. Chem. 14, 243-248.
114. Lahoz, C.; Pena, R.; Mostaza, J. M.; Jimenez, J.; Subirats, E.; Pinto, X.; Taboada, M. and Lopez-Pastor, A. (2003) Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 168, 289-295.
115. Lahoz, C.; Pena, R.; Mostaza, J. M.; Laguna, F.; Garcia-Iglesias, M. F.; Taboada, M. and Pinto, X. (2005a) The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 182, 129-134.
116. Lahoz, C.; Pena, R.; Mostaza, J. M.; Laguna, F.; Garcia-Iglesias, M. F.; Taboada, M. and Pinto, X. (2005b) Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism 54, 741-747.
117. Lampe, J. W.; Bigler, J.; Horner, N. K. and Potter, J. D. (1999) UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9, 341-349.
118. Lange, L. A.; Carlson, C. S.; Hindorff, L. A.; Lange, E. M.; Walston, J.; Durda, J. P.; Cushman, M.; Bis, J. C.; Zeng, D.; Lin, D.; Kuller, L. H.; Nickerson, D. A.; Psaty, B. M.; Tracy, R. P. and Reiner, A. P. (2006) Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 296, 2703-2711.
119. Lee, C. G.; Chong, S. S. and Lee, E. J. D. (2004) Pharmacogenetics of the human MDR1 multidrug transporter. Curr. Pharmacogenomics 2, 1-11.
120. Lee, E.; Ryan, S.; Birmingham, B.; Zalikowski, J.; March, R.; Ambrose, H.; Moore, R.; Lee, C.; Chen, Y. and Schneck, D. (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341.
121. Lee, S. S.; Jeong, H. E.; Yi, J. M.; Jung, H. J.; Jang, J. E.; Kim, E. Y.; Lee, S. J. and Shin, J. G. (2007) Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab. Dispos. 35, 623-632.
122. Leitersdorf, E.; Eisenberg, S.; Eliav, O.; Friedlander, Y.; Berkman, N.; Dann, E. J.; Landsberger, D.; Sehayek, E.; Meiner, V.; Wurm, M. and et al. (1993) Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 87, III35-III44.
123. Li, A. P.; Kaminski, D. L. and Rasmussen, A. (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104, 1-8.
124. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M. and Collins, R. (2008) SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359, 789-799.
125. Lutucuta, S.; Ballantyne, C. M.; Elghannam, H.; Gotto, A. M., Jr. and Marian, A. J. (2001) Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity,
126. Mackenzie, P. I.; Bock, K. W.; Burchell, B.; Guillemette, C.; Ikushiro, S.; Iyanagi, T.; Miners, J. O.; Owens, I. S. and Nebert, D. W. (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 15, 677-685.
127. Mahley, R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
128. Maitland-van der Zee, A. H.; Jukema, J. W.; Zwinderman, A. H.; Hallman, D. M.; De Boer, A.; Kastelein, J. J. and De Knijff, P. (2006) Apolipoprotein- E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta. Cardiol. 61, 327-331.
129. Malin, R.; Laaksonen, R.; Knuuti, J.; Janatuinen, T.; Vesalainen, R.; Nuutila, P. and Lehtimaki, T. (2001) Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11, 625-633.
130. Marzolini, C.; Paus, E.; Buclin, T. and Kim, R. B. (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33.
131. McCaskie, P. A.; Beilby, J. P.; Chapman, C. M.; Hung, J.; McQuillan, B. M.; Thompson, P. L. and Palmer, L. J. (2007) Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease. Hum. Genet. 121, 401-411.
132. Medina, M. W.; Gao, F.; Ruan, W.; Rotter, J. I. and Krauss, R. M. (2008) Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118, 355-362.
133. Meyer, U. A. and Zanger, U. M. (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-96.
134. Mizuarai, S.; Aozasa, N. and Kotani, H. (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 109, 238-246.
135. Mohrschladt, M. F.; van der Sman-de Beer, F.; Hofman, M. K.; van der Krabben, M.; Westendorp, R. G. and Smelt, A. H. (2005) TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur. J. Hum. Genet. 13, 877-882.
136. Morrison, A. C.; Bare, L. A.; Chambless, L. E.; Ellis, S. G.; Malloy, M.; Kane, J. P.; Pankow, J. S.; Devlin, J. J.; Willerson, J. T. and Boerwinkle, E. (2007) Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am. J. Epidemiol. 166, 28-35.
137. Muck, W.; Unger, S.; Kawano, K. and Ahr, G. (1998) Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br. J. Clin. Pharmacol. 45, 583-590.
138. Mulder, A. B.; van Lijf, H. J.; Bon, M. A.; van den Bergh, F. A.; Touw, D. J.; Neef, C. and Vermes, I. (2001) Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharmacol. Ther. 70, 546-551.
139. Mwinyi, J.; Kopke, K.; Schaefer, M.; Roots, I. and Gerloff, T. (2008) Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur. J. Clin. Pharmacol. 64, 257-266.
140. Nagassaki, S.; Sertorio, J. T.; Metzger, I. F.; Bem, A. F.; Rocha, J. B. and Tanus-Santos, J. E. (2006) eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic. Biol. Med. 41, 1044-1049.
141. Nestel, P.; Simons, L.; Barter, P.; Clifton, P.; Colquhoun, D.; Hamilton- Craig, I.; Sikaris, K. and Sullivan, D. (1997) A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 129, 231-239.
142. Neuvonen, P. J.; Niemi, M. and Backman, J. T. (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565-581.
143. Niemi, M.; Neuvonen, P. J.; Hofmann, U.; Backman, J. T.; Schwab, M.; Lutjohann, D.; von Bergmann, K.; Eichelbaum, M. and Kivisto, K. T. (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics 15, 303-309.
144. Niemi, M.; Arnold, K. A.; Backman, J. T.; Pasanen, M. K.; Godtel- Armbrust, U.; Wojnowski, L.; Zanger, U. M.; Neuvonen, P. J.; Eichelbaum, M.; Kivisto, K. T. and Lang, T. (2006) Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance- associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics 16, 801-808.
145. Nishizato, Y.; Ieiri, I.; Suzuki, H.; Kimura, M.; Kawabata, K.; Hirota, T.; Takane, H.; Irie, S.; Kusuhara, H.; Urasaki, Y.; Urae, A.; Higuchi, S.; Otsubo, K. and Sugiyama, Y. (2003) Polymorphisms of OATPC (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565.
146. Noe, J.; Stieger, B. and Meier, P. J. (2002) Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123, 1659-1666.
147. Nordin, C.; Dahl, M. L.; Eriksson, M. and Sjoberg, S. (1997) Is the cholesterol- lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet 350, 29-30.
148. Nozawa, T.; Nakajima, M.; Tamai, I.; Noda, K.; Nezu, J.; Sai, Y.; Tsuji, A. and Yokoi, T. (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813.
149. Nozawa, T.; Minami, H.; Sugiura, S.; Tsuji, A. and Tamai, I. (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33, 434-439.
150. O'Malley, J. P. and Illingworth, D. R. (1990) The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 39, 150-154.
151. O'Neill, F. H.; Patel, D. D.; Knight, B. L.; Neuwirth, C. K.; Bourbon, M.; Soutar, A. K.; Taylor, G. W.; Thompson, G. R. and Naoumova, R. P. (2001) Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 21, 832-783.
152. Ordovas, J. M.; Lopez-Miranda, J.; Perez-Jimenez, F.; Rodriguez, C.; Park, J. S.; Cole, T. and Schaefer, E. J. (1995) Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113, 157-166.
153. Ozawa, S.; Soyama, A.; Saeki, M.; Fukushima-Uesaka, H.; Itoda, M.; Koyano, S.; Sai, K.; Ohno, Y.; Saito, Y. and Sawada, J. (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ ABCB1. Drug Metab. Pharmacokinet. 19, 83-95.
154. Palumbo, G.; Bacchi, S.; Palumbo, P.; Primavera, L. G. and Sponta, A. M. (2005) [Grapefruit juice: potential drug interaction]. Clin. Ther. 156, 97-103.
155. Park, K. W.; Choi, J. H.; Kim, H. K.; Oh, S.; Chae, I. H.; Kim, H. S.; Oh, B. H.; Lee, M. M.; Park, Y. B. and Choi, Y. S. (2003) The association of cholesteryl ester transfer protein polymorphism with highdensity lipoprotein cholesterol and coronary artery disease in Koreans. Clin. Genet. 63, 31-38.
156. Pasanen, M. K.; Backman, J. T.; Neuvonen, P. J. and Niemi, M. (2006a) Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415.
157. Pasanen, M. K.; Neuvonen, M.; Neuvonen, P. J. and Niemi, M. (2006b) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-889.
158. Pasanen, M. K.; Fredrikson, H.; Neuvonen, P. J. and Niemi, M. (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726-733.
159. Pasanen, M. K.; Neuvonen, P. J. and Niemi, M. (2008) Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9, 19-33.
160. Pedro-Botet, J.; Schaefer, E. J.; Bakker-Arkema, R. G.; Black, D. M.; Stein, E. M.; Corella, D. and Ordovas, J. M. (2001) Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158, 183-193.
161. Pena, R.; Lahoz, C.; Mostaza, J. M.; Jimenez, J.; Subirats, E.; Pinto, X.; Taboada, M. and Lopez-Pastor, A. (2002) Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med. 251, 518-525.
162. Pisciotta, L.; Fasano, T.; Bellocchio, A.; Bocchi, L.; Sallo, R.; Fresa, R.; Colangeli, I.; Cantafora, A.; Calandra, S. and Bertolini, S. (2007) Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 194, e116-e122.
163. Po, A. L. (2007) Personalised medicine: who is an Asian? Lancet 369, 1770-1771.
164. Prueksaritanont, T.; Gorham, L. M.; Ma, B.; Liu, L.; Yu, X.; Zhao, J. J.; Slaughter, D. E.; Arison, B. H. and Vyas, K. P. (1997) In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 25, 1191-1199.
165. Prueksaritanont, T.; Ma, B.; Fang, X.; Subramanian, R.; Yu, J. and Lin, J. H. (2001) beta-Oxidation of simvastatin in mouse liver preparations. Drug Metab. Dispos. 29, 1251-1255.
166. Prueksaritanont, T.; Subramanian, R.; Fang, X.; Ma, B.; Qiu, Y.; Lin, J. H.; Pearson, P. G. and Baillie, T. A. (2002a) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30, 505-512.
167. Prueksaritanont, T.; Zhao, J. J.; Ma, B.; Roadcap, B. A.; Tang, C.; Qiu, Y.; Liu, L.; Lin, J. H.; Pearson, P. G. and Baillie, T. A. (2002b) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 301, 1042-1051.
168. Prueksaritanont, T.; Ma, B. and Yu, N. (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 56, 120-124.
169. Puccetti, L.; Pasqui, A. L.; Pastorelli, M.; Ciani, F.; Palazzuoli, A.; Gioffre, W.; Auteri, A. and Bruni, F. (2005) 3′UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis 183, 322-328.
170. Puccetti, L.; Pasqui, A. L.; Bruni, F.; Pastorelli, M.; Ciani, F.; Palazzuoli, A.; Pontani, A.; Ghezzi, A. and Auteri, A. (2007) Lectin-like oxidized- LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int. J. Cardiol. 119, 41-47.
171. Remmler, C. and Cascorbi, I. (2008) Pharmacogenomics in acute coronary syndrome. Expert Opin. Pharmacother. 9, 363-376.
172. Ridker, P. M. (2007) C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 49, 2129-2138.
173. Ridker, P. M. and Cook, N. R. (2007) Biomarkers for prediction of cardiovascular events. N. Engl. J. Med. 356, 1472-1473.
174. Roberts, W. C. (1997) The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol. 80, 106-107.
175. Roy, J. N.; Lajoie, J.; Zijenah, L. S.; Barama, A.; Poirier, C.; Ward, B. J. and Roger, M. (2005) CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884-887.
176. Ruano, G.; Thompson, P. D.; Windemuth, A.; Seip, R. L.; Dande, A.; Sorokin, A.; Kocherla, M.; Smith, A.; Holford, T. R. and Wu, A. H. (2007) Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 36, 329-335.
177. Sabatine, M. S.; Ploughman, L.; Simonsen, K. L.; Iakoubova, O. A.; Kirchgessner, T. G.; Ranade, K.; Tsuchihashi, Z.; Zerba, K. E.; Long, D. U.; Tong, C. H.; Packard, C. J.; Pfeffer, M. A.; Devlin, J. J.; Shepherd, J.; Campos, H.; Sacks, F. M. and Braunwald, E. (2008) Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler. Thromb. Vasc. Biol. 28, 562-567.
178. Saito, Y.; Maekawa, K.; Ozawa, S. and Sawada, J. (2007) Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr. Pharmacogenomics 5, 49-78.
179. Salek, L.; Lutucuta, S.; Ballantyne, C. M.; Gotto Jr, A. M. and Marian, A. J. (2002) Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J. Mol. Med. 80, 737-744.
180. Sandhu, M. S.; Waterworth, D. M.; Debenham, S. L.; Wheeler, E.; Papadakis, K.; Zhao, J. H.; Song, K.; Yuan, X.; Johnson, T.; Ashford, S.; Inouye, M.; Luben, R.; Sims, M.; Hadley, D.; McArdle, W.; Barter, P.; Kesaniemi, Y. A.; Mahley, R. W.; McPherson, R.; Grundy, S. M.; Bingham, S. A.; Khaw, K. T.; Loos, R. J.; Waeber, G.; Barroso, I.; Strachan, D. P.; Deloukas, P.; Vollenweider, P.; Wareham, N. J. and Mooser, V. (2008) LDL-cholesterol concentrations: a genome-wide association study. Lancet 371, 483-491.
181. Sanllehy, C.; Casals, E.; Rodriguez-Villar, C.; Zambon, D.; Ojuel, J.; Ballesta, A. M. and Ros, E. (1998) Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 47, 560-565.
182. Sata, F.; Sapone, A.; Elizondo, G.; Stocker, P.; Miller, V. P.; Zheng, W.; Raunio, H.; Crespi, C. L. and Gonzalez, F. J. (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56.
183. Schmitz, G. and Langmann, T. (2006) Pharmacogenomics of cholesterol-lowering therapy. Vascul. Pharmacol. 44, 75-89.
184. Schmitz, G.; Schmitz-Madry, A. and Ugocsai, P. (2007) Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr. Opin. Lipidol. 18, 164-173.
185. Schwarz, U. I. (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur. J. Clin. Invest. 33(Suppl 2), 23-30.
186. Shiffman, D.; Chasman, D. I.; Zee, R. Y.; Iakoubova, O. A.; Louie, J. Z.; Devlin, J. J. and Ridker, P. M. (2008) A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J. Am. Coll. Cardiol. 51, 444-448.
187. Shitara, Y.; Hirano, M.; Sato, H. and Sugiyama, Y. (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236.
188. Shitara, Y. and Sugiyama, Y. (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71-105.
189. Siest, G.; Marteau, J. B.; Maumus, S.; Berrahmoune, H.; Jeannesson, E.; Samara, A.; Batt, A. M. and Visvikis-Siest, S. (2005) Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. Eur. J. Pharmacol. 527, 1-22.
190. Sijbrands, E. J.; Lombardi, M. P.; Westendorp, R. G.; Leuven, J. A.; Meinders, A. E.; Van der Laarse, A.; Frants, R. R.; Havekes, L. M. and Smelt, A. H. (1998) Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 136, 247-254.
191. Simonson, S. G.; Raza, A.; Martin, P. D.; Mitchell, P. D.; Jarcho, J. A.; Brown, C. D.; Windass, A. S. and Schneck, D. W. (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76, 167-177.
192. Singer, J. B.; Holdaas, H.; Jardine, A. G.; Fellstrom, B.; Os, I.; Bermann, G. and Meyer, J. M. (2007) Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J. Lipid Res. 48, 2072-2078.
193. Sinues, B.; Vicente, J.; Fanlo, A.; Vasquez, P.; Medina, J. C.; Mayayo, E.; Conde, B.; Arenaz, I. and Martinez-Jarreta, B. (2007) CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther. Drug Monit. 29, 412-416.
194. Soutar, A. K. and Naoumova, R. P. (2007) Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4, 214-225.
195. Souza-Costa, D. C.; Sandrim, V. C.; Lopes, L. F.; Gerlach, R. F.; Rego, E. M. and Tanus-Santos, J. E. (2007) Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193, 438-444.
196. Staud, F. and Pavek, P. (2005) Breast cancer resistance protein (BCRP/ ABCG2). Int. J. Biochem. Cell Biol. 37, 720-725.
197. Suchy, F. J. and Ananthanarayanan, M. (2006) Bile salt excretory pump: biology and pathobiology. J. Pediatr. Gastroenterol. Nutr. 43, (Suppl 1), S10-S16.
198. Suk, H. J.; Ridker, P. M.; Cook, N. R. and Zee, R. Y. (2005) Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 178, 139-145.
199. Sun, X. M.; Patel, D. D.; Knight, B. L. and Soutar, A. K. (1998) Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group. Atherosclerosis 136, 175-185.
200. Tachibana-Iimori, R.; Tabara, Y.; Kusuhara, H.; Kohara, K.; Kawamoto, R.; Nakura, J.; Tokunaga, K.; Kondo, I.; Sugiyama, Y. and Miki, T. (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375-380.
201. Takahashi-Yasuno, A.; Masuzaki, H.; Miyawaki, T.; Ogawa, Y.; Matsuoka, N.; Hayashi, T.; Hosoda, K.; Inoue, G.; Yoshimasa, Y. and Nakao, K. (2003) Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men. Diabetes Res. Clin. Pract. 62, 169-175.
202. Tang, K.; Ngoi, S. M.; Gwee, P. C.; Chua, J. M.; Lee, E. J.; Chong, S. S. and Lee, C. G. (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12, 437-450.
203. Tang, W. and Stearns, R. A. (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug Metab. 2, 185-198.
204. Tavintharan, S.; Lim, S. C.; Chan, Y. H. and Sum, C. F. (2007) Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 9, 81-86.
205. Thompson, J. F.; Man, M.; Johnson, K. J.; Wood, L. S.; Lira, M. E.; Lloyd, D. B.; Banerjee, P.; Milos, P. M.; Myrand, S. P.; Paulauskis, J.; Milad, M. A. and Sasiela, W. J. (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5, 352-358.
206. Tirona, R. G.; Leake, B. F.; Merino, G. and Kim, R. B. (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675.
207. Tirona, R. G. (2005) Ethnic differences in statin disposition. Clin. Pharmacol. Ther. 78, 311-316.
208. Tomlinson, B.; Chan, P. and Lan, W. (2001) How well tolerated are lipid-lowering drugs? Drugs Aging 18, 665-683.
209. Tomlinson, B.; Hu, M. and Lee, V. W. Y. (2008) In vivo assessment of herb - drug interactions: Possible utility of a pharmacogenetic approach? Mol. Nutr. Food Res. 52, 799-809.
210. Trompet, S.; Pons, D.; De Craen, A. J.; Slagboom, P.; Shepherd, J.; Blauw, G. J.; Murphy, M. B.; Cobbe, S. M.; Bollen, E. L.; Buckley, B. M.; Ford, I.; Hyland, M.; Gaw, A.; Macfarlane, P. W.; Packard, C. J.; Norrie, J.; Perry, I. J.; Stott, D. J.; Sweeney, B. J.; Twomey, C.; Westendorp, R. G. and Jukema, J. W. (2007) Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study. Ann. N. Y. Acad. Sci. 1100, 189-198.
211. Tsai, M. Y.; Johnson, C.; Kao, W. H.; Sharrett, A. R.; Arends, V. L.; Kronmal, R.; Jenny, N. S.; Jacobs, D. R., Jr.; Arnett, D.; O'Leary, D. and Post, W. (2008) Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 200(2), 359-367.
212. Tukey, R. H. and Strassburg, C. P. (2000) Human UDP-glucuronosyl-transferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616.
213. van Helvoort, A.; Smith, A. J.; Sprong, H.; Fritzsche, I.; Schinkel, A. H.; Borst, P. and van Meer, G. (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87, 507-517.
214. van Venrooij, F. V.; Stolk, R. P.; Banga, J. D.; Sijmonsma, T. P.; van Tol, A.; Erkelens, D. W. and Dallinga-Thie, G. M. (2003) Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 26, 1216-1223.
215. Varret, M.; Abifadel, M.; Rabes, J. P. and Boileau, C. (2008) Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin. Genet. 73, 1-13.
216. Vohl, M. C.; Szots, F.; Lelievre, M.; Lupien, P. J.; Bergeron, J.; Gagne, C. and Couture, P. (2002) Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 160, 361-368.
217. von Richter, O.; Burk, O.; Fromm, M. F.; Thon, K. P.; Eichelbaum, M. and Kivisto, K. T. (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther. 75, 172-183.
218. Wang, A.; Yu, B. N.; Luo, C. H.; Tan, Z. R.; Zhou, G.; Wang, L. S.; Zhang, W.; Li, Z.; Liu, J. and Zhou, H. H. (2005) Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol. 60, 843-848.
219. Wang, D. and Sadee, W. (2006) Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). Aaps. J. 8, E515-E520.
220. Watanabe, H.; Kosuge, K.; Nishio, S.; Yamada, H.; Uchida, S.; Satoh, H.; Hayashi, H.; Ishizaki, T. and Ohashi, K. (2004) Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 76, 281-292.
221. Watanabe, J.; Kobayashi, K.; Umeda, F.; Yamauchi, T.; Mimura, K.; Nakashima, N.; Masakado, M.; Hiramatsu, S. and Nawata, H. (1993) Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients. Diabetes Res. Clin. Pract. 20, 21-27.
222. Willer, C. J.; Sanna, S.; Jackson, A. U.; Scuteri, A.; Bonnycastle, L. L.; Clarke, R.; Heath, S. C.; Timpson, N. J.; Najjar, S. S.; Stringham, H. M.; Strait, J.; Duren, W. L.; Maschio, A.; Busonero, F.; Mulas, A.; Albai, G.; Swift, A. J.; Morken, M. A.; Narisu, N.; Bennett, D.; Parish, S.; Shen, H.; Galan, P.; Meneton, P.; Hercberg, S.; Zelenika, D.; Chen, W. M.; Li, Y.; Scott, L. J.; Scheet, P. A.; Sundvall, J.; Watanabe, R. M.; Nagaraja, R.; Ebrahim, S.; Lawlor, D. A.; Ben-Shlomo, Y.; Davey-Smith, G.; Shuldiner, A. R.; Collins, R.; Bergman, R. N.; Uda, M.; Tuomilehto, J.; Cao, A.; Collins, F. S.; Lakatta, E.; Lathrop, G. M.; Boehnke, M.; Schlessinger, D.; Mohlke, K. L. and Abecasis, G. R. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40, 161-169.
223. Winkelmann, B. R.; Hoffmann, M. M.; Nauck, M.; Kumar, A. M.; Nandabalan, K.; Judson, R. S.; Boehm, B. O.; Tall, A. R.; Ruano, G. and Marz, W. (2003) Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J. 3, 284-296.
224. Xie, H. G.; Kim, R. B.; Wood, A. J. and Stein, C. M. (2001) Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850.
225. Yeo, K. R.; Yeo, W. W.; Wallis, E. J. and Ramsay, L. E. (1999) Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br. J. Clin. Pharmacol. 48, 610-615.
226. Zamber, C. P.; Lamba, J. K.; Yasuda, K.; Farnum, J.; Thummel, K.; Schuetz, J. D. and Schuetz, E. G. (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13, 19-28.
227. Zambon, A.; Deeb, S. S.; Brown, B. G.; Hokanson, J. E. and Brunzell, J. D. (2001) Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 103, 792-798.
228. Zanger, U. M.; Raimundo, S. and Eichelbaum, M. (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37.
229. Zhang, W.; Yu, B. N.; He, Y. J.; Fan, L.; Li, Q.; Liu, Z. Q.; Wang, A.; Liu, Y. L.; Tan, Z. R.; Fen, J.; Huang, Y. F. and Zhou, H. H. (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta. 373, 99-103.
230. Zhang, W.; Chen, B. L.; Ozdemir, V.; He, Y. J.; Zhou, G.; Peng, D. D.; Deng, S.; Xie, Q. Y.; Xie, W.; Xu, L. Y.; Wang, L. C.; Fan, L.; Wang, A. and Zhou, H. H. (2007) SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol. 64, 346-352.
231. Zuccaro, P.; Mombelli, G.; Calabresi, L.; Baldassarre, D.; Palmi, I. and Sirtori, C. R. (2007) Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 55, 310-317.